This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The combination medication amlodipine/atorvastatin will have improved insulin resistance, increased adherence, and enhanced pleiotropic effects of endothelial function, inflammation, oxidative stress, and coagulation when compared to co-adminstered HCTZ and atorvastatin. This study will - 1. Compare the plieotropic effects of Amlodipine vs. HCTZ when added to a statin on: a. endothelial function: via brachial artery laser probe b. inflammation: by measuring serum hsCRP, IL-6, and TNFol c. Oxidative stess: by measuring serum TBAR, Lp-PLA2, glutathionine peroxidase, and MDA d. Coagulation: by masuring serum PAI-1 and homocysteine 2. To determine if there is a dose response curve of atrovastatin, amlodipine and HCTZ on these pleiotropic effects. 3. To determine the effects of HCTZ versus Amlodipine on insulin resistance in patients treated with a statin by measuring HOMA and adiponectin. 4. To determine the effects of these two agents on the nocturnal dip in blood pressure in patients treated with a statin. 5. To compare adherence and rates of attaining JNC VII and NCEP III goals for hypertension andhyperlididemia with combination Amlodipine/atorvastatin (1 pill) versus co-administered HCTZ and Atorvastatin (2 pills).